Weight management with macupatide and eloralintide, alone or together

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, master protocol study examines the body weight lowering effects and safety of macupatide and eloralintide, alone or in combination, in adults with overweight or obesity who do not have type 2 diabetes. Participants are followed for about 64 weeks, with randomization to receive the study drugs or placebo under a controlled clinical setting. The trial uses a shared protocol framework (CWMM) to standardize eligibility and assessments across arms. Primary outcomes focus on weight loss and safety signals, with monitoring for cardiovascular and pancreatic adverse events. Locations include cardiovascular/hepatology research centers in Arizona, enrolling eligible adults according to the overarching protocol’s criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion Criteria:

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

* Have type 1 diabetes or type 2 diabetes
* Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
* Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
* Have a history of acute or chronic pancreatitis
* All concomitant medications should be at a stable dose for at least 3 months prior to screening

Where it's running

• The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
  Chandler, Arizona, United States Recruiting
• Headlands Research - Scottsdale
  Scottsdale, Arizona, United States Recruiting
• The Institute for Liver Health II dba Arizona Liver Health-Tucson
  Tucson, Arizona, United States Recruiting
• NorCal Medical Research, Inc
  Greenbrae, California, United States Recruiting
• Velocity Clinical Research, Huntington Park
  Huntington Park, California, United States Recruiting
• Peninsula Research Associates
  Rolling Hills Estates, California, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.